Zacks Research Has Bullish Forecast for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at Zacks Research upped their Q1 2026 EPS estimates for shares of Exelixis in a note issued to investors on Tuesday, July 1st. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of $0.55 per share for the quarter, up from their previous forecast of $0.54. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q2 2026 earnings at $0.61 EPS, FY2026 earnings at $2.54 EPS and Q1 2027 earnings at $0.67 EPS.

Other analysts have also recently issued reports about the stock. Stifel Nicolaus boosted their price objective on shares of Exelixis from $36.00 to $38.00 and gave the company a “hold” rating in a research note on Wednesday, May 14th. Citigroup upped their price target on shares of Exelixis from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, May 15th. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the stock a “buy” rating in a research report on Tuesday, June 24th. Benchmark reaffirmed a “neutral” rating on shares of Exelixis in a research report on Monday, June 23rd. Finally, HC Wainwright upped their price target on shares of Exelixis from $47.00 to $53.00 and gave the stock a “buy” rating in a research report on Monday, June 30th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $43.56.

Exelixis Stock Up 3.6%

Shares of NASDAQ EXEL opened at $45.91 on Thursday. Exelixis has a 52-week low of $21.86 and a 52-week high of $49.62. The firm has a fifty day moving average of $41.88 and a 200-day moving average of $37.65. The stock has a market capitalization of $12.52 billion, a PE ratio of 20.87, a P/E/G ratio of 0.93 and a beta of 0.28.

Insider Buying and Selling

In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $46.18, for a total value of $1,154,500.00. Following the sale, the executive vice president owned 693,396 shares in the company, valued at approximately $32,021,027.28. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 100,000 shares of the company’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $46.00, for a total transaction of $4,600,000.00. Following the completion of the sale, the chief financial officer owned 967,842 shares in the company, valued at approximately $44,520,732. This trade represents a 9.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock worth $21,024,817 over the last quarter. Company insiders own 2.82% of the company’s stock.

Institutional Investors Weigh In On Exelixis

A number of institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC raised its stake in shares of Exelixis by 21.0% in the 1st quarter. Voya Investment Management LLC now owns 327,296 shares of the biotechnology company’s stock valued at $12,084,000 after purchasing an additional 56,708 shares in the last quarter. Modern Wealth Management LLC acquired a new stake in shares of Exelixis in the 1st quarter valued at about $251,000. Strs Ohio acquired a new stake in shares of Exelixis in the 1st quarter valued at about $2,267,000. Ellsworth Advisors LLC acquired a new stake in shares of Exelixis in the 1st quarter valued at about $3,589,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 944 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.